**Core tip:** Although intratumoral human epidermal growth factor receptor 2 (HER2) heterogeneity has been reported as an important predictor of trastuzumab-based chemotherapy for HER2-positive breast cancer, the clinical significance of HER2 heterogeneity for gastric cancer had been unclear. We defined intratumoral HER2 heterogeneity as biopsy specimens were taken from two or more different portions of the tumor that showed different HER2 positivity by immunohistochemistry, and HER2 heterogeneity based on this definition was a pivotal poor predictor of tumor shrinkage and poor prognosticator. Thus, intratumoral HER2 heterogeneity should be included in the assessment of HER2 positivity.

INTRODUCTION
============

Human epidermal growth factor receptor 2 (HER2) was introduced as a predictive biomarker for the treatment of gastric cancer along with trastuzumab\[[@B1]\], and trastuzumab was subsequently recommended to be administered for HER2-positive gastric cancer as a molecular target drug\[[@B2],[@B3]\]. Assessment of HER2 expression was performed by immunohistochemistry (IHC) and in-situ hybridization (ISH), where positive HER2 expression was defined as 3+ on IHC or 2+ on IHC with ISH positive\[[@B4]\]. The strong HER2 intensity of IHC 3+ was reported as a better prognostic factor for HER2-positive gastric cancer treated with trastuzumab-based chemotherapy\[[@B1]\].

The frequency of intratumoral HER2 heterogeneity was reported as 45%-79% by IHC and 23%-54% by ISH for HER2-positive gastric cancers\[[@B5]-[@B8]\], which were more frequent than that with HER2-positive breast cancers\[[@B9]\]. Although intratumoral HER2 heterogeneity was reported to be one of the poor predictors for treatment response and poor prognosticator for patients with HER2-positive breast cancer who received trastuzumab-based chemotherapy\[[@B10],[@B11]\], the clinical significance of intratumoral HER2 heterogeneity for HER2 positive gastric cancer treated with trastuzumab has not been well investigated. Recently, Wakatsuki et al\[[@B12]\] reported that intratumoral HER2 heterogeneity had a negative survival benefit for patients with surgically resected HER2-positive gastric cancer. However, HER2 assessment before treatment is usually based on the endoscopic biopsy specimen for metastatic gastric cancer, and the clinical significance of intratumoral HER2 heterogeneity for biopsy specimen is still unknown.

The aim of this study was to clarify the clinical significance of intratumoral HER2 heterogeneity for HER2 positive gastric cancer treated with trastuzumab-based chemotherapy by evaluation of biopsy specimens.

MATERIALS AND METHODS
=====================

Patients and data collection
----------------------------

Patients with histologically confirmed HER2-positive metastatic or unresectable adenocarcinoma of the stomach or gastroesophageal junction cancer who received trastuzumab-based chemotherapy as first-line treatment at our hospital between July 2011 and December 2017 were included in this study. The patients were classified into two groups according to intratumoral HER2 heterogeneity, and their clinico-pathological findings, clinical responses, progression-free survival (PFS) and overall survival (OS) were compared. Furthermore, the predictive factor for clinical response and prognostic factor were analyzed using multivariable analyses. We extracted clinicopathological findings such as age, sex, tumor diameter, tumor location, macroscopic tumor type, tumor markers, Eastern Cooperative Oncology Group performance score, TNM stage, metastatic site, chemotherapy regimen, histological type of endoscopic biopsy specimen, HER2 positivity, survival outcomes from our prospectively collected database and medical records. Biopsied specimens stained by IHC were reviewed and assessed for their intratumoral HER2 heterogeneity by two pathologists (A.K. and T.K.).

Patients who received gastrectomy prior to chemotherapy and patients who received chemotherapy without trastuzumab were excluded. Clinical response was evaluated according to new response evaluation criteria in solid tumors (RECIST guideline ver. 1.1) for patients with measurable metastatic lesions\[[@B13]\]. The onset of PFS was defined as the start of chemotherapy, and tumor progression was evaluated by imaging techniques and physical examination. Tumor progression dates for patients who received radical gastrectomy after good clinical response to chemotherapy were defined as the date of first recurrence after surgery. Tumor staging of gastric and EGJ type III tumor followed the Union for International Cancer Control TNM classification of 7^th^ edition for gastric cancer, and tumor staging of EGJ type II tumor followed that for esophageal cancer\[[@B14]\]. Tumor histology was assessed according to the Japanese Classification of Gastric Carcinoma\[[@B15]\], with well and moderately differentiated adenocarcinoma and papillary adenocarcinoma classified as differentiated type, and poorly differentiated adenocarcinoma, signet ring cell carcinoma, and mucinous carcinoma classified as undifferentiated type.

Treatment schedules
-------------------

Chemotherapy regimens were capecitabine or 5-fluorouracil plus cisplatin with trastuzumab (XPT/FPT) before September 2015 and S-1 plus oxaliplatin with trastuzumab (SOXT) after October 2015. XPT or FPT regimens were followed a ToGA study regimen\[[@B1]\]. SOXT regimen was followed according to the G-SOX study regimen in combination with trastuzumab; oxaliplatin was administered intravenously 100 mg/m^2^ on day 1, while S-1 was administered orally 80 mg/m^2^ for 14 d followed by a 7-d rest. This schedule was repeated every 3 wk. Trastuzumab was given by intravenous infusion at a dose of 8 mg/kg on day 1 of the first cycle, followed by 6 mg/kg every 3 wk until disease progression\[[@B16]\].

HER2 immunohistochemistry and fluorescence in situ hybridization
----------------------------------------------------------------

All endoscopic biopsy samples were fixed in neutral buffered 10% formalin. Formalin-fixed paraffin-embedded tumor samples were examined for HER2 using IHC and fluorescence in situ hybridization (FISH) when the HER2 score was 2+.

HER2 IHC analyses were performed using the PATHWAY anti-HER-2/neu (4B5) rabbit monoclonal primary antibody (Ventana Medical Systems, Tucson, AZ, United States). IHC HER2 scoring by biopsy specimen was performed as described in the ToGA study\[[@B1]\]. In brief, tumor cell clusters of at least five positive cells with complete basolateral or lateral membranous reactivity was considered HER2-positive for endoscopic biopsy samples irrespective of percentage of tumor cells stained. Tumor cells with strong membranous reactivity were scored 3+, and those with moderate reactivity were scored 2+. HER2 FISH analyses were performed at SRL (Tokyo, Japan) using the Path Vysion HER2 DNA Probe kit (Vysis, Downers Grove, IL, United States). When the ratio of HER2 signals to chromosome 17 centromere signals was 2.0 or greater, the gene was considered amplified (*i.e*., FISH-positive). HER2 positivity was defined as IHC score 3+ or IHC score 2+ and FISH positivity, because these criteria were considered to be indications for using trastuzumab by a subset analysis of the ToGA trial\[[@B1],[@B3]\].

Assessment of intratumoral HER2 heterogeneity
---------------------------------------------

Assessment of intratumoral HER2 heterogeneity was conducted on patients who underwent assessment of HER2 positivity from two or more different portions of the same tumor, and three or more biopsy specimens were obtained from each portion. Those patients whose HER2 assessment was performed from only one portion were excluded for further examination. Intratumoral HER2 homogeneity was defined as every portion being HER2-positive by IHC, and if any portion of the tumor was HER2-negative, the tumor was defined as intratumoral HER2 heterogeneity (Figure [1](#F1){ref-type="fig"}).

![Assessment of intratumoral HER2 heterogeneity. Assessment of intratumoral HER2 heterogeneity was conducted from at least two different portions of the same tumor, and more than three biopsy specimens were obtained from each portion. Homogeneity was defined by all assessed portions showing HER2 positivity, and heterogeneity was defined as a tumor with any portions that did not show HER2 positivity. HER2: Human epidermal growth factor receptor 2.](WJCC-7-1964-g001){#F1}

Statistical analysis
--------------------

The baseline characteristics of each group were compared using the χ^2^ test or the Fisher's exact test for categorical data, and *P* \< 0.05 was considered statistically significant. The median OS rate and PFS rate were estimated by the Kaplan-Meier method. Independent prognostic factors for OS and PFS were evaluated by univariate and multivariable analysis of Cox proportional hazard model and presented as hazard ratio and 95% confidence interval (CI). Evaluated factors in multivariable analysis were those that were significant by univariate analysis. Data were censored on May 31, 2019. All statistical analyses were performed using SPSS Statistics 20 (SPSS Inc., Chicago, IL, United States).

This study was approved by the Institutional Review Board of the National Cancer Center, Japan (IRB file No. 2017-164, approval date: Oct. 11, 2017).

RESULTS
=======

A total of 776 patients with metastatic or unresectable adenocarcinoma of the stomach or gastroesophageal junction were treated in this study period, and HER2 positivity was observed in 127 cases (16.3%). Of these, patients who received upfront gastrectomy before chemotherapy (*n* = 5) or chemotherapy without trastuzumab (*n* = 21), and patients who underwent HER2 assessment from only one portion of the tumor (*n* = 13) were excluded (Figure [2](#F2){ref-type="fig"}). Finally, a group of 88 patients were evaluated for intratumoral HER2 heterogeneity, in which HER2 homogeneity was observed in 65 (Homo group) and HER2 heterogeneity was observed in 23 (Hetero group) patients.

![Patient flow chart. HER2 positivity was observed in 127 (16.3%) of 776 patients with metastatic or unresectable adenocarcinoma. After exclusion of 39 patients for the listed reasons, HER2 homogeneity was observed in 65 (Homo group) and HER2 heterogeneity was observed in 23 (Hetero group). HER2: Human epidermal growth factor receptor 2.](WJCC-7-1964-g002){#F2}

Patients' backgrounds are shown in Table [1](#T1){ref-type="table"}. Intratumoral HER2 heterogeneity was significantly more frequently observed in macroscopically type 3 and type 4 patients than other types, and in patients with IHC 2+ compared to IHC 3+. Other background characteristics such as age, sex, performance status, TNM stage, metastatic site and chemotherapeutic regimens were not significantly different between the groups. Besides, the number of biopsy sites for HER2 assessment was not significantly different, *i.e*., those numbers more than three was 46% for Homo group and 57% for Hetero group (*P* = 0.393). Waterfall plot for tumor shrinkage and clinical responses for the patients with measurable metastatic lesions (*n* = 58) of both groups are shown in Figure [3](#F3){ref-type="fig"}. Overall response rate (complete response and partial response) was 79.5% in the Homo group, which was considerably better than that in the Hetero group (35.7%, *P* = 0.002). Kaplan-Meier curves of OS and PFS in both groups are shown in Figure [4](#F4){ref-type="fig"}. At the time of the analysis, the median follow-up was 18.5 mo (range, 4.7-88.0 mo). The median survival time (MST) in the Hetero group was 12.5 mo, which was considerably worse than that in the Homo group (25.7 mo, HR; 2.430, 95%CI: 1.389-4.273). Median PFS time in the Hetero group was 2.9 mo, which was also significantly worse than that in the Homo group (7.9 mo, HR: 2.000, 95%CI: 1.203-3.333). Multivariate analysis revealed IHC HER2 heterogeneity as one of the independent poor prognostic factors for OS (HR: 3.115, 95%CI: 1.610-6.024) and PFS (HR: 2.123, 95%CI: 1.225-3.676) (Table [2](#T2){ref-type="table"}). Undifferentiated histological type (HR: 2.612, 95%CI: 1.388-4.916), number of non-curative factors (HR: 2.252, 95%CI: 1.113-4.553), clinical nodal status (HR: 2.119, 95%CI: 1.165-3.855), hepatic metastasis (HR: 2.084, 95%CI: 1.076-4.036) and HER2 score (2+) (HR: 2.008, 95%CI: 1.094-3.690) were also extracted as independent poor prognostic factors for OS. We compared survival results by the combination of each HER2 score (2+ or 3+) and HER2 heterogeneity (homogeneity or heterogeneity). MST for the Homo group with HER2 3+ was longest (28.2 mo), followed by Hetero group with 3+ (14.6 mo) and Homo group with 2+ (12.9 mo). Hetero group with 2+ had the worst prognosis (MST: 7.2 mo) (Figure [5](#F5){ref-type="fig"}).

###### 

Patients' demographic information

                                  **Homo, *n* = 65**   **Hetero, *n* = 23**   ***P*-value**
  ------------------------------- -------------------- ---------------------- ---------------------
  Age in yr                       69 (42-81)           67.0 (45-82)           
  \< 70                           34 (52%)             15 (65%)               0.284
  ≥ 70                            31 (48%)             8 (35%)                
  Sex                                                                         
  Male                            43 (66%)             18 (78%)               0.279
  Female                          22 (34%)             5 (22%)                
  ECOG performance status                                                     
  0                               61 (94%)             20 (87%)               0.152
  1                               2 (3%)               3 (13%)                (0 *vs* ≥ 1)
  2                               2 (3%)               0                      
  Macroscopic type                                                            
  1                               7 (11%)              1 (5%)                 0.008
  2                               28 (43%)             4 (17%)                (type 1/2 *vs* 3/4)
  3                               23 (35%)             16 (69%)               
  4                               7 (11%)              2 (9%)                 
  Tumor location                                                              
  Upper                           27 (42%)             11 (48%)               0.601
  Middle / lower                  38 (58%)             12 (52%)               
  Histology                                                                   
  Well differentiated             48 (74%)             14 (61%)               0.31
  Poorly differentiated           15 (23%)             9 (39%)                
  Other/unknown                   2 (3%)               0                      
  T status                                                                    
  cT2                             2 (3%)               0                      0.267
  cT3                             17 (26%)             4 (17%)                (cT2/3 *vs* cT4)
  cT4                             46 (71%)             19 (83%)               
  N status                                                                    
  cN0                             5 (8%)               2 (9%)                 0.748
  cN1                             5 (8%)               1 (4%)                 (≤cN2 *vs* cN3)
  cN2                             32 (49%)             11 (48%)               
  cN3                             23 (35%)             9 (39%)                
  Number of non-curative factor                                               
  0                               1 (1%)               1 (4%)                 0.404
  1                               32 (49%)             13 (57%)               (≤1 *vs* \>1)
  2                               29 (45%)             9 (39%)                
  \>2                             3 (5%)               0                      
  Non-curative factor                                                         
  Lymph node                      34 (52%)             10 (43%)               
  Peritoneal                      22 (34%)             6 (26%)                
  Hepatic                         27 (42%)             12 (52%)               
  Other                           9 (14%)              1 (5%)                 
  Number of HER2 assessment                                                   
  2                               35 (54%)             10 (43%)               0.393
  3                               27 (42%)             13 (57%)               
  \>3                             3 (4%)               0                      
  HER2 score                                                                  
  3+                              53 (82%)             10 (43%)               0.001
  2+                              12 (18%)             13 (57%)               
  Upfront chemotherapy                                                        
  SOXT                            33 (50%)             12 (52%)               
  XPT                             25 (37%)             7 (30%)                
  SPT                             3 (5%)               2 (9%)                 
  FPT                             1 (2%)               2 (9%)                 
  FLT                             1 (2%)                                      
  PTXT                            1 (2%)                                      
  DCST                            1 (2%)                                      

ECOG: Eastern Cooperative Oncology Group; SOXT: S-1 oxaliplatin capecitabine trastuzumab; XPT: capecitabine cisplatin trastuzumab; SPT: S-1 cisplatin trastuzumab; FPT: 5-Fluorouracil cisplatin trastuzumab; FLT: 5-Fluorouracil leucovorin trastuzumab; PTXT: Paclitaxel trastuzumab; DCST: Docetaxel cisplatin S-1 trastuzumab.

###### 

Prognostic factors for overall survival and progression-free survival

  **Covariates**                            **Overall survival**   **Progression-free survival**                                                                                     
  ----------------------------------------- ---------------------- ------------------------------- --------------------- ------- --------------------- ------- --------------------- -------
  Age, ≥ 80 *vs* \< 80                      1.31 (0.473-3.625)     0.604                                                         1.138 (0.492-2.633)   0.762                         
  Sex, female *vs* male                     1.057 (0.621-1.798)    0.838                                                         1.005 (0.615-1.642)   0.985                         
  Macroscopic type, type 3,4 *vs* 1,2       1.72 (1.027-2.881)     0.039                                                         1.641 (1.037-2.598)   0.034                         
  Clinical tumor depth, cT4 *vs* ≤ cT3      1.838(0.992-3.405)     0.053                                                         1.408 (0.826-2.401)   0.209                         
  Clinical nodal status, cN3 *vs* ≤ cN2     2.026 (1.184-3.466)    0.01                            2.119 (1.165-3.855)   0.014   1.691 (1.056-2.708)   0.029   1.622 (0.951-2.764)   0.076
  Histology, undiff. *vs* diff.             1.884 (1.090-3.255)    0.023                           2.612 (1.388-4.916)   0.003   1.643 (1.031-2.618)   0.037   1.902 (1.117-3.237)   0.018
  HER2 score, 2+ *vs* 3+                    2.331 (1.353-4.016)    0.002                           2.008 (1.094-3.690)   0.024   1.828 (1.110-3.012)   0.018   1.612 (0.940-2.770)   0.083
  HER2 heterogeneity, hetero *vs* homo      2.439 (1.389-4.274)    0.002                           3.115 (1.610-6.024)   0.001   2 (1.203-3.333)       0.008   2.123 (1.225-3.676)   0.007
  No. of non-curative factors, ≥ 2 *vs* 1   1.904 (1.138-3.186)    0.014                           2.252 (1.113-4.553)   0.024   1.875 (1.185-2.965)   0.007   1.871 (1.023-3.424)   0.042
  M1, lymph node                            0.687 (0.410-1.150)    0.154                                                         0.568 (0.358-0.902)   0.017                         
  M1, peritoneal                            1.207 (0.699-2.086)    0.5                                                           1.327 (0.828-2.127)   0.24                          
  M1, hepatic                               1.902 (1.141-3.173)    0.014                           2.084 (1.076-4.036)   0.029   1.974 (1.244-3.132)   0.004   2.053 (1.151-3.664)   0.015

HER2: Human epidermal growth factor receptor 2; HR: Hazard ratio.

![Clinical response for patients with or without intratumoral human epidermal growth factor receptor 2 heterogeneity. Tumor shrinkage (left) and clinical response (right) was evaluated by RECIST ver. 1.1 for 58 patients who have measurable metastatic lesions. ORR was 79.5% in the Homo group, which was significantly higher than that in the Hetero group (35.7%, *P* = 0.002). CR: Complete response; PR: Partial response; SD: Stable disease; PD: Progressive disease; ORR: Overall response rate (CR plus PR).](WJCC-7-1964-g003){#F3}

![OS and PFS with or without intratumoral human epidermal growth factor receptor 2 heterogeneity. Kaplan-Meier curves of OS (left) and PFS (right) in both groups was shown with the median follow-up of 18.5 mo (range, 4.7-88.0 mo). MST and median PST in the Hetero group were significantly worse than those in the Homo group. MST: Median survival time; HR: Hazard ratio; CI: Confidence interval; OS: Overall survival; PFS: Progression-free survival.](WJCC-7-1964-g004){#F4}

![Overall survival by HER2 score and intratumoral HER2 heterogeneity. MST for the Homo group with HER2 3+ was longest (28.2 mo), followed by Hetero group with 3+ (14.6 mo), Homo group with 2+ (12.9 mo) and Hetero group with 2+ (7.2 mo). MST: Median survival time; HR: Hazard ratio; CI: Confidence interval; HER2: Human epidermal growth factor receptor 2.](WJCC-7-1964-g005){#F5}

DISCUSSION
==========

In this study, we examined the effect of intratumoral HER2 heterogeneity by IHC for HER2-positive advanced gastric cancer treated with trastuzumab-based chemotherapy on their therapeutic responses and survival. Intratumoral HER2 heterogeneity by IHC evaluated by biopsy specimen before treatment was one of the independent poor predictive factors for tumor shrinkage and a poor prognosticator.

The definition of intratumoral HER2 heterogeneity for HER2-positive gastric cancer has not been well established. The cut-off value between HER2 homogeneity and heterogeneity of HER2 positive tumor cells varies from 50% to 100% for surgically resected specimens\[[@B5],[@B6],[@B12],[@B17]\] and 30% to 100% for endoscopic biopsy specimens\[[@B7],[@B8],[@B18]\]. The clinical significance of intratumoral HER2 heterogeneity for HER2-positive gastric cancer treated with trastuzumab has not been well investigated, and there have been only a few studies conducted to date. Wakatsuki et al\[[@B12]\] defined the cut-off value of HER2 heterogeneity as 100% and reported that HER2 homogeneity group had significantly longer PFS (HR: 0.11, 95%CI: 0.03-0.41) and OS (HR: 0.18, 95%CI: 0.06-0.72). However, their study included only 28 patients who received trastuzumab-based chemotherapy after upfront gastrectomy for resectable gastric cancer, not metastatic cancer.

In post hoc exploratory analyses of the ToGA trial, the proportion of HER2-positive tumor cells in more than 30% of biopsy specimens could not be extracted as a predictive factor for good response to trastuzumab-based chemotherapy\[[@B18]\]. Yagi et al\[[@B8]\] recently reported that intratumoral HER2 heterogeneity was a poor predictor for trastuzumab-based chemotherapy and a poor prognosticator with the cut-off value of 100% from the median number of four biopsy specimens. Our current study selected patients in whom HER2 positivity could be assessed from more than two different portions of the tumor, and we defined HER2 heterogeneity as any of those tumor portions being negative for HER2. The number of biopsy specimens examined for each patient in our current study was more than six (*i.e*., each of the three fragments were obtained from two or more different portions). Although Yagi et al\[[@B8]\] adopted the overall proportion of HER2-positive tumor cells to evaluate intratumoral HER2 heterogeneity, we employed the standard criteria of HER2 positivity generally performed in clinical diagnosis, *i.e*., tumor cell cluster of at least five positive cells with complete basolateral or lateral membranous reactivity. According to our simple definition of intratumoral HER2 heterogeneity, the treatment outcomes were definitively different between the HER2 homogeneity group and heterogeneity group.

The stain intensity for IHC was reported as a significant prognostic factor for HER2-positive gastric cancer in the ToGA trial. The OS was significantly longer in IHC 3+ patients than IHC 2+ patients (MST: 17.9 and 12.3 mo)\[[@B1]\]. Assessment of HER2 positivity for endoscopic biopsy specimen in the ToGA trial was established without consideration of intratumor HER2 heterogeneity, which is now commonly adopted worldwide\[[@B4]\]. Prognostic significance of stain intensity for IHC was also explored in combination with heterogeneity for IHC in our current study. MST of Homo-IHC 3+ patients was 28.2 mo, which was much better than MST of IHC 3+ patients (17.9 mo) in the ToGA trial. Hetero-IHC 3+ and Homo-IHC 2+ patients had comparable survival (14.6 and 12.9 mo), while Hetero-IHC 2+ patients had poorer survival (7.2 mo) compared to IHC 2+ patients (12.3 mo) in the ToGA trial. These results suggest that intratumoral HER2 heterogeneity should be included in the assessment of HER2 positivity in addition to the stain intensity for IHC, and patients with Homo-IHC 3+ might be the most responsive to further anti-HER2 agents. The survival benefits for anti-HER2 drugs such as lapatinib or pertuzumab in combination with trastuzumab and adjuvant therapy of trastuzumab or trastuzumab beyond progression have been demonstrated for breast cancers\[[@B19]-[@B22]\]. However, the efficacy of those anti-HER2 agents has not been shown for gastric cancers, and intratumoral HER2 heterogeneity may be one of the reasons for the difference of these results between breast and gastric cancers\[[@B23],[@B24]\].

Although the intrinsic mechanism underlying the correlation between HER2 heterogeneity and poor efficacy of trastuzumab-based chemotherapy is still unclear, chemo-resistance can be one of the main reasons for the treatment failure. Fabi et al\[[@B25]\] reported that the discordances of HER2 positivity between primary and metastatic lesions may be a possible cause of chemo-resistance of trastuzumab for metastatic breast cancers. Park et al\[[@B26]\] reported these discordances between primary and metastatic lesions could also be observed in HER2-positive gastric cancers, and HER2 heterogeneity of primary lesions existed in such cases with discordances of HER2 positivity. Another explanation for the poor efficacy of trastuzumab might be genomic alterations. Pietrantonio et al\[[@B27]\] reported that chemo-resistance against trastuzumab was more frequently observed in patients with genomic alternations including *EGFR*/*MET*/*KRAS*/*PI3K*/*PTEN* mutations than those without. They stated such genomic mutations were correlated with IHC 2+, *i.e*., the existence of HER2 heterogeneity.

Our study has several limitations. First, concordance of intratumoral HER2 heteroge-neity between endoscopic biopsy specimen and whole tumor tissues was not investigated in the current study. The concordance of HER2 positivity between biopsy specimens and surgically resected specimens was reported to be 80%-91% for IHC 3+ and 25%-57% for IHC 2+ patients\[[@B28]-[@B30]\], thus the interpretation of HER2 heterogeneity for IHC 2+ patients must be made with care. In breast cancer, similar results have been reported comparing core needle biopsy specimens and surgically resected specimens\[[@B31]\], and repeat testing or reflex testing using an alternative assay (IHC or ISH) are recommended for IHC equivocal cases\[[@B32]\]. Secondly, there was no common standard of adequate numbers and portions for the assessment of intratumoral HER2 heterogeneity. In this study, the assessment of intratumoral HER2 heterogeneity was performed from at least two portions of the tumor. Ohno et al\[[@B33]\] reported that HER2 positivity was different in different tumor regions, *i.e*., the frequency of HER2 positivity in the biopsy specimen from the superficial spreading portion, ulcer mound, and mass portion was as high as 90% to 100%, while these from ulcer bed was only 45% due to the presence of concomitant necrotic tissues and associated inflammation\[[@B34]\]. These results suggest that the assessment of HER2 heterogeneity should be based on biopsy specimens taken from the appropriate portion of the tumor. Thirdly, this study did not include the intratumoral heterogeneity of *HER2* gene amplification. Intratumoral heterogeneity of *HER2* gene amplification has been reported to be a significant prognostic factors for metastatic or resectable advanced breast cancers\[[@B9],[@B11]\]. The significance of intratumoral heterogeneity of *HER2* gene amplification should also be clarified in further investigations.

In conclusion, intratumoral HER2 heterogeneity by IHC was a significant predictor of clinical response and a poor prognosticator for trastuzumab-based chemotherapy. Thus, intratumoral HER2 heterogeneity would be useful to further stratify patients with HER2-positive gastric cancer, and thus should be taken into account in future clinical trials.

ARTICLE HIGHLIGHTS
==================

Research background
-------------------

Human epidermal growth factor receptor 2 (HER2) was introduced as a predictive biomarker for the treatment of gastric cancer along with trastuzumab, and the strong HER2 intensity of immunohistochemistry (IHC) 3+ was reported as a better prognostic factor for HER2-positive gastric cancer treated with trastuzumab-based chemotherapy. Intratumoral HER2 heterogeneity for HER2-positive gastric cancers was reported to be more frequent than in HER2-positive breast cancers. Although intratumoral HER2 heterogeneity was reported to be one of the poor predictors for the treatment response and poor prognosticator for patients with HER2-positive breast cancer who received trastuzumab-based chemotherapy, the clinical significance of intratumoral HER2 heterogeneity for HER2-positive gastric cancer treated with trastuzumab has not been well investigated. Furthermore, even the definitions of HER2 heterogeneity for HER2-positive gastric cancer have not been established. In this study, we established the definition of intratumoral HER2 heterogeneity and clarified the clinical significance of HER2 heterogeneity for HER2-positive gastric cancer.

Research motivation
-------------------

HER2 heterogeneity may be a pivotal predictor for the efficacy of trastuzumab-based chemotherapy. Authors have previously reported that intratumoral HER2 heterogeneity had a negative survival benefit for patients with surgically resected HER2-positive gastric cancer. However, HER2 assessment before treatment is usually based on endoscopic biopsy specimen for metastatic gastric cancer, and the clinical significance of intratumoral HER2 heterogeneity for biopsy specimen is still unknown. If these clinical significances are clarified, HER2 heterogeneity might be introduced to the assessment of HER2 positivity for gastric cancer in the future.

Research objectives
-------------------

The aim of this study was to clarify the clinical significance of intratumoral HER2 heterogeneity for HER2-positive gastric cancer treated with trastuzumab-based chemotherapy by evaluation of biopsy specimens.

Research methods
----------------

Patients with HER2-positive metastatic or unresectable adenocarcinoma of the stomach or gastroesophageal junction who received trastuzumab-based chemotherapy as first-line treatment at our hospital were included. The patients were classified into two groups (Homo- and Hetero- group) according to intratumoral HER2 heterogeneity, and their clinicopathological findings, clinical responses, progression-free survival (PFS) and overall survival (OS) were compared. Furthermore, the predictive factor for clinical response and prognostic factor were analyzed using multivariable analyses. Assessment of intratumoral HER2 heterogeneity was conducted on patients who underwent assessment of HER2 positivity from two or more different portions of the same tumor, and three or more biopsy specimens were obtained from each portion. Those patients whose HER2 assessment was performed from only one portion were excluded. We defined intratumoral HER2 homogeneity as every portion of the tumor being HER2-positive by IHC, and any portion of the tumor staining negative for HER2 was defined as intratumoral HER2 heterogeneity.

Research results
----------------

A total of 776 patients with metastatic or unresectable adenocarcinoma of the stomach or gastroesophageal junction were treated in the study period, and HER2 positivity was observed in 127 patients (16.3%). Intratumoral HER2 heterogeneity was significantly more frequently observed in macroscopically type 3 and type 4 patients than other types, and patients with IHC 2+ than IHC 3+. Tumor shrinkage and clinical responses for the patients with measurable metastatic lesions were evaluated, and overall response rate (complete response and partial response) was considerably better in the Homo group than in the Hetero group. Median survival time in the Hetero group was 12.5 mo, which was considerably worse than that in the Homo group (25.7 mo, HR; 2.430, 95%CI: 1.389-4.273). Median PFS time in the Hetero group was 2.9 mo, which was also significantly worse than that in the Homo group (7.9 mo, HR: 2.000, 95%CI: 1.203-3.333). Multivariate analysis revealed IHC HER2 heterogeneity as one of the independent poor prognostic factors for OS (HR: 3.115, 95%CI: 1.610-6.024) and PFS (HR: 2.123, 95%CI: 1.225-3.676).

Research conclusions
--------------------

In this study, we examined the effect of intratumoral HER2 heterogeneity by IHC for HER2-positive advanced gastric cancer treated with trastuzumab-based chemotherapy on their therapeutic responses and survival. Intratumoral HER2 heterogeneity by IHC evaluated by biopsy specimen before treatment was one of the independent poor predictive factors for tumor shrinkage and a poor prognosticator. Our current study selected patients in whom HER2 positivity could be assessed from more than two different portions of the tumor, and we newly defined HER2 heterogeneity as any of those portions of the tumor that did not show HER2 positivity. We employed the standard criteria of HER2 positivity generally performed in clinical diagnosis, *i.e*., tumor cell cluster of at least five positive cells with complete basolateral or lateral membranous reactivity. According to our simple definition of intratumoral HER2 heterogeneity, the treatment outcomes were definitively different between the HER2 homogeneity group and heterogeneity group. Assessment of HER2 positivity for endoscopic biopsy specimen in the ToGA trial was established without consideration of intratumor HER2 heterogeneity. Our current study suggests that the combination of heterogeneity and IHC might be beneficial to predict the efficacy of trastuzumab-based chemotherapy.

Research perspectives
---------------------

HER2 heterogeneity is a pivotal predictor for the efficacy of HER2-positive gastric cancers. However, there are still some problems that need to be solved in the future. First, concordance of intratumoral HER2 heterogeneity between endoscopic biopsy specimen and whole tumor tissues has not been investigated in the current study. Secondly, there was no common standard of adequate numbers and portions for the assessment of intratumoral HER2 heterogeneity. Thirdly, this study did not include the intratumoral heterogeneity of HER2 gene amplification. Intratumoral heterogeneity of *HER2* gene amplification has been reported to be one of the significant prognostic factors for metastatic or resectable advanced breast cancers. The significance of intratumoral heterogeneity of *HER2* gene amplification should also be clarified by further investigations. The survival benefits for anti-HER2 drugs such as lapatinib or pertuzumab in combination with trastuzumab and adjuvant therapy of trastuzumab or trastuzumab beyond progression were demonstrated for breast cancers. However, the efficacy of those anti-HER2 agents had not been proven for gastric cancers, and intratumoral HER2 heterogeneity may be considered as one of the reasons for the difference of these results between breast and gastric cancers. If more detailed clinical significance of intratumoral HER2 heterogeneity is solved in the future, anti-HER2 drugs other than trastuzumab can be adopted, and treatment outcomes of HER2-positive gastric cancers would be improved.
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